Discontinue Venlafaxine (Effexor) First
In a patient with possible bipolar II on venlafaxine and bupropion who needs mood stabilization, discontinue venlafaxine first because it carries the highest risk of inducing mood switches to hypomania or mania among antidepressants used in bipolar disorder.
Evidence-Based Rationale for Discontinuing Venlafaxine
Venlafaxine's Superior Switch Risk
Venlafaxine demonstrates a significantly elevated risk of threshold switches (full-duration hypomania ≥7 days or mania) compared with bupropion or sertraline in bipolar depression, with the ratio of threshold switches to subthreshold brief hypomanias reaching 3.60 in acute trials and 3.75 in continuation trials 1
In direct comparative trials, venlafaxine was associated with significantly increased risk of switches into hypomania or mania compared with bupropion or sertraline when used as adjuncts to mood stabilizers in bipolar depression 2
The FDA label for venlafaxine explicitly warns that treating a major depressive episode with an antidepressant alone may increase the likelihood of precipitating a mixed/manic episode in patients at risk for bipolar disorder, and emphasizes the need to screen patients for bipolar disorder before initiating treatment 3
Bupropion's Relative Safety Profile
Bupropion exhibits the lowest relative risk of mood switching among the three antidepressants studied (bupropion, sertraline, venlafaxine), with a ratio of threshold switches to subthreshold brief hypomanias of only 0.85 in acute trials and 1.17 in continuation trials 1
In difficult-to-treat, severely ill bipolar depressive inpatients, bupropion as add-on therapy to mood stabilizers produced no switches from depression to hypomania or mania when doses were kept at or below 450 mg daily 4
Expert consensus and practicing clinicians recommend bupropion as a coequal initial choice with SSRIs for bipolar depression, with the risk of antidepressant-induced hypomania or mania with concomitant mood stabilizer therapy estimated at only 5-10% during acute phase therapy 5
Recommended Discontinuation Protocol
Venlafaxine Tapering Schedule
Taper venlafaxine gradually over 2-4 weeks rather than stopping abruptly to avoid discontinuation syndrome characterized by dizziness, fatigue, nausea, sensory disturbances, anxiety, and irritability 6
Reduce the dose by approximately 25% every 1-2 weeks (e.g., if on 150 mg daily: 150 mg → 112.5 mg → 75 mg → 37.5 mg → 0 mg) to minimize withdrawal symptoms 6
The FDA label warns that abrupt discontinuation of venlafaxine can be associated with certain symptoms, and medication should be tapered as rapidly as feasible while recognizing these risks 3
Timing of Mood Stabilizer Initiation
Initiate a mood stabilizer (lithium, valproate, or lamotrigine) before beginning the venlafaxine taper to prevent a therapeutic gap that could precipitate mood destabilization 7
Lithium is recommended as first-line treatment for bipolar disorder with target levels of 0.8-1.2 mEq/L for acute treatment, and it demonstrates superior evidence for long-term efficacy in maintenance therapy 7
Valproate shows higher response rates (53%) compared to lithium (38%) in children and adolescents with mania and mixed episodes, and is particularly effective for irritability and mixed presentations 7
Lamotrigine is approved for maintenance therapy in bipolar disorder and is particularly effective for preventing depressive episodes 7
Maintaining Bupropion During Transition
Continue bupropion at its current dose while tapering venlafaxine and initiating the mood stabilizer, as bupropion can be safely combined with mood stabilizers and has demonstrated efficacy in treatment-refractory bipolar depression 8, 4
Bupropion's noradrenergic/dopaminergic mechanism of action may play a more prominent role in bipolar depression and can be useful in both acute and maintenance treatment 8
Co-medication with bupropion and various mood stabilizers including lithium and sodium valproate has been shown to be safe 4
Critical Monitoring During Transition
Weekly Assessment Parameters
Monitor for emergence of manic symptoms (decreased need for sleep, increased energy, racing thoughts, impulsivity, grandiosity) at each visit during the venlafaxine taper 3
Assess for venlafaxine discontinuation symptoms including agitation, irritability, anxiety, dizziness, sensory disturbances, and gastrointestinal symptoms 6, 3
Evaluate mood stability, suicidal ideation, sleep patterns, and adherence to the new mood stabilizer regimen weekly during the first month 7
The FDA label emphasizes monitoring for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment changes 3
Common Pitfalls to Avoid
Never discontinue venlafaxine abruptly, as this dramatically increases the risk of severe discontinuation syndrome and potential mood destabilization 6
Never allow antidepressant monotherapy in bipolar disorder—always ensure a mood stabilizer is on board before completing the venlafaxine taper 7
Do not start the mood stabilizer after completing the venlafaxine taper, as this creates a dangerous therapeutic gap that could precipitate a mood episode 7
Avoid tapering both medications simultaneously—maintain bupropion at a stable dose while managing the venlafaxine discontinuation 9
Do not misinterpret discontinuation symptoms as mood destabilization—withdrawal symptoms from venlafaxine typically emerge within days and are self-limiting, whereas true mood episodes develop more gradually over weeks 6
Expected Timeline and Outcomes
Expect the complete transition to take 4-6 weeks: 1-2 weeks to reach therapeutic mood stabilizer levels, followed by 2-4 weeks for venlafaxine taper 6
In only 16.2% of acute antidepressant trials was there sustained antidepressant response in the continuation phase without a threshold switch, highlighting the importance of proper mood stabilization 1
Threshold switches into full-duration hypomania and mania occurred in 11.4% and 7.9% of acute treatment trials, and 21.8% and 14.9% of continuation trials, with higher rates in bipolar I (30.8%) than bipolar II (18.6%) 1
Schedule follow-up within 1-2 weeks after initiating the mood stabilizer and again after completing the venlafaxine taper to assess for mood destabilization, suicidal ideation, or worsening symptoms 9